Recent Progress in Multiple Sclerosis Treatment Using Immune Cells as Targets

被引:8
作者
Ma, Xiaohong [1 ,2 ]
Ma, Rong [3 ]
Zhang, Mengzhe [3 ]
Qian, Baicheng [1 ]
Wang, Baoliang [1 ]
Yang, Weijing [3 ]
机构
[1] Henan Univ Chinese Med, Affiliated Hosp 1, Dept Neurosci, Zhengzhou 450000, Peoples R China
[2] Henan Univ Chinese Med, Clin Med Sch 1, Zhengzhou 450046, Peoples R China
[3] Zhengzhou Univ, Sch Pharmaceut Sci, Henan Key Lab Targeting Therapy & Diag Crit Dis, Zhengzhou 450001, Peoples R China
基金
中国国家自然科学基金;
关键词
multiple sclerosis; immunotherapy; T cells; B cells; innate immune cells; REGULATORY T-CELLS; PLACEBO-CONTROLLED TRIAL; MYELIN BASIC-PROTEIN; GLATIRAMER ACETATE; B-CELLS; DENDRITIC CELLS; DOUBLE-BLIND; IFN-BETA; MENINGEAL INFLAMMATION; NEUROMYELITIS-OPTICA;
D O I
10.3390/pharmaceutics15030728
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Multiple sclerosis (MS) is an autoimmune-mediated demyelinating disease of the central nervous system. The main pathological features are inflammatory reaction, demyelination, axonal disintegration, reactive gliosis, etc. The etiology and pathogenesis of the disease have not been clarified. The initial studies believed that T cell-mediated cellular immunity is the key to the pathogenesis of MS. In recent years, more and more evidence has shown that B cells and their mediated humoral immune and innate immune cells (such as microglia, dendritic cells, macrophages, etc.) also play an important role in the pathogenesis of MS. This article mainly reviews the research progress of MS by targeting different immune cells and analyzes the action pathways of drugs. The types and mechanisms of immune cells related to the pathogenesis are introduced in detail, and the mechanisms of drugs targeting different immune cells are discussed in depth. This article aims to clarify the pathogenesis and immunotherapy pathway of MS, hoping to find new targets and strategies for the development of therapeutic drugs for MS.
引用
收藏
页数:20
相关论文
共 189 条
  • [1] Effects of Vitamin D3, Calcipotriol and FTY720 on the Expression of Surface Molecules and Cytolytic Activities of Human Natural Killer Cells and Dendritic Cells
    Al-Jaderi, Zaidoon
    Maghazachi, Azzam A.
    [J]. TOXINS, 2013, 5 (11) : 1932 - 1947
  • [2] From Leflunomide to Teriflunomide: Drug Development and Immunosuppressive Oral Drugs in the Treatment of Multiple Sclerosis
    Aly, Lilian
    Hemmer, Bernhard
    Korn, Thomas
    [J]. CURRENT NEUROPHARMACOLOGY, 2017, 15 (06) : 874 - 891
  • [3] Construction of a lncRNA-miRNA-mRNA network to determine the key regulators of the Th1/Th2 imbalance in multiple sclerosis
    Azari, Hanieh
    Karimi, Elham
    Shekari, Mohammad
    Tahmasebi, Ahmad
    Nikpoor, Amin Reza
    Negahi, Ahmad Agha
    Sanadgol, Nima
    Mousavi, Pegah
    [J]. EPIGENOMICS, 2021, 13 (22) : 1797 - 1816
  • [4] Experimental autoimmune encephalomyelitis is a good model of multiple sclerosis if used wisely
    Baker, David
    Amor, Sandra
    [J]. MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2014, 3 (05) : 555 - 564
  • [5] Cellular immunology of relapsing multiple sclerosis: interactions, checks, and balances
    Bar-Or, Amit
    Li, Rui
    [J]. LANCET NEUROLOGY, 2021, 20 (06) : 470 - 483
  • [6] Teriflunomide and Its Mechanism of Action in Multiple Sclerosis
    Bar-Or, Amit
    Pachner, Andrew
    Menguy-Vacheron, Francoise
    Kaplan, Johanne
    Wiendl, Heinz
    [J]. DRUGS, 2014, 74 (06) : 659 - 674
  • [7] Abnormal B-Cell Cytokine Responses A Trigger of T-Cell Mediated Disease in MS?
    Bar-Or, Amit
    Fawaz, Lama
    Fan, Boli
    Darlington, Peter J.
    Rieger, Aja
    Ghorayeb, Christine
    Calabresi, Peter A.
    Waubant, Emmanuelle
    Hauser, Stephen L.
    Zhang, Jiameng
    Smith, Craig H.
    [J]. ANNALS OF NEUROLOGY, 2010, 67 (04) : 452 - 461
  • [8] More stories on Th17 cells
    Basso, Alexandre S.
    Cheroutre, Hilde
    Mucida, Daniel
    [J]. CELL RESEARCH, 2009, 19 (04) : 399 - 411
  • [9] Beghi E, 2019, LANCET NEUROL, V18, P357, DOI [10.1016/S1474-4422(19)30034-1, 10.1016/S1474-4422(18)30454-X, 10.1016/S1474-4422(18)30443-5]
  • [10] Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells
    Bettelli, E
    Carrier, YJ
    Gao, WD
    Korn, T
    Strom, TB
    Oukka, M
    Weiner, HL
    Kuchroo, VK
    [J]. NATURE, 2006, 441 (7090) : 235 - 238